Henrik Griesser

Laboratory Medicine Dr. Wisplinghoff
Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Cytopathology Terminology Systems: European Federation of Cytological Societies Survey on Practice in Europe.

Cytopathology Terminology Systems: European Federation of Cytological Societies Survey on Practice in Europe.

Journal: Cytopathology : official journal of the British Society for Clinical Cytology

Published: February 16, 2026

Dysbiotic Co-Factors in Cervical Cancer. How the Microbiome Influences the Development of Cervical Intraepithelial Neoplasia (CIN).

Dysbiotic Co-Factors in Cervical Cancer. How the Microbiome Influences the Development of Cervical Intraepithelial Neoplasia (CIN).

Journal: Geburtshilfe und Frauenheilkunde

Published: December 09, 2022

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.

Journal: Geburtshilfe und Frauenheilkunde

Published: September 29, 2021

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

Journal: Geburtshilfe und Frauenheilkunde

Published: September 29, 2021

Indications for p16/Ki-67 in cervical cytology

Indications for p16/Ki-67 in cervical cytology

Journal: Der Pathologe

Published: January 14, 2017

HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.

HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.

Journal: Anticancer research

Published: September 10, 2014

Remarks on the "Comments on the Publication of Munich Nomenclature III by the Cytology Coordination Conference" by A. Schneider and P. Hillemanns (Geburtsh Frauenheilk 2014; 74: 242-243).

Remarks on the "Comments on the Publication of Munich Nomenclature III by the Cytology Coordination Conference" by A. Schneider and P. Hillemanns (Geburtsh Frauenheilk 2014; 74: 242-243).

Journal: Geburtshilfe und Frauenheilkunde

Published: August 08, 2014

Predictive value of the combined p16 and Ki-67 immunocytochemistry in low-grade squamous intraepithelial lesions.

Predictive value of the combined p16 and Ki-67 immunocytochemistry in low-grade squamous intraepithelial lesions.

Journal: Acta cytologica

Published: May 26, 2014

Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.

Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.

Journal: Journal of the National Cancer Institute

Published: October 08, 2013

HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study.

HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: August 06, 2012

Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.

Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.

Journal: Maturitas

Published: September 30, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026